Psilocybin mushroom grown per mezzo di Littleton, Colo. Use of the psychoactive drug is growing per mezzo di popularity per mezzo di the U.S.
Hyoung Chang/Denver Post/Getty Images
hide caption
toggle caption
Hyoung Chang/Denver Post/Getty Images
Psychedelics have entered the mainstream per mezzo di a personaggio way: Investors have staked billions acceso potential medical treatments, scientific research has skyrocketed and public sentiment signals growing acceptance.
And yet the major sources of acceso drug use have personaggio gaps when it comes to psychedelics, making it duro to gauge exactly how consumption is changing and per mezzo di what ways.
Two reports out this week offer some much-needed points acceso the public’s psychoactive preferences. Together, they suggest that psilocybin-containing mushrooms are now the most popular choice. And many people are opting to microdose, consuming a fraction of the usual parte, rather than taking a full trip.
“We’ve known that microdosing has become a cultural phenomenon, but all the surveys acceso drug use don’t ask about dosing,” says Eric Leas, an epidemiologist at the University of California, San Diego, whose research was published acceso Friday per mezzo di JAMA Health Riunione.
That study tracked internet search history acceso microdosing – a proxy for public interest – finding about a 1,250% increase since 2015. And searches for psilocybin started to outpace LSD per mezzo di 2019.
Meanwhile, a separate report from the non-partisan RAND Corporation estimates that about 3% of the American public – approximately 8 million adults – have used psilocybin per mezzo di the past year, making it the most popular hallucinogen per mezzo di 2023.
The fact that psilocybin use eclipsed other popular psychedelics came as a “surprise” to Beau Kilmer, who co-directs the RAND Drug Policy Research Center and was the lead author of the study, which was published this week.
The runner-up was MDMA, ora ecstasy, at just over 1%, followed closely by LSD. The report was based acceso a nationally representative survey of about 4,000 people and explores the policy implications of changing attitudes around psychedelics.
The impact of decriminalization acceso microdosing
Nearly half of those who tried psilocybin per mezzo di the past year said they had elected to microdose, a trend that has caught acceso per mezzo di many circles, including tech workers and suburban moms.
While there’s anzi che no universal definition of microdosing, Kilmer says it’s often considered to be per mezzo di the range of 1/10 to 1/20th of a full parte.
Some users dabble per mezzo di mushrooms. The majority of psilocybin microdosers per mezzo di the past year said they had taken the drug acceso just one ora two occasions, while only about 11% said they had taken the substance more than six days.
More than half said they consumed “whole, fresh, ora dried mushrooms,” close to a quarter took it per mezzo di a “processed form” like a chocolate , and about 14% imbibed a tea ora bevanda.
The uptick per mezzo di online curiosity around microdosing correlates with changes per mezzo di the law ora policy related to both cannabis and psychedelics.
“There was a stepwise increase to where the more and more liberal the state got to substance use, the more microdosing interest you saw within the state,” says UCSD’s Leas.
For example, the cima states were Oregon and Colorado, both states decriminalized plant-derived psychedelics, although Oregon has recently reigned per mezzo di some of its legal reforms around drug use.
This type of analysis has proven to be a reliable indicator for other drugs their lab has studied – including with novel cannabis products like 8 – and, Leas says, is “usually really strongly correlated with sales of products.”
Are ‘shrooms the new drug?
Research suggests that availability of psilocybin has risen per mezzo di recent years, says Joseph Palamar, an epidemiologist at NYU Langone Health who has found that drug busts for mushrooms have increased per mezzo di recent years.
Palamar cautions about drawing too many conclusions from internet search history about whether people are actually using the drugs, but he says the study is a much-needed effort at filling per mezzo di the blind spots per mezzo di the epidemiology around psychedelic use.
“We’signore trying to piece little bits of information together to figure out what is really going acceso. Ultimately, it would be great if we could harmonize these somehow, but it’s very difficult,” he says.
Palamar researches trends per mezzo di drug use per mezzo di the New York City nightlife scene – a population that he considers a bellwether for changes per mezzo di the general population.
“We’ve found that psilocybin use has increased a lot, more than most other drugs,” he says, “I think that’s interesting because I usually think of ecstasy and ketamine, I never thought of shrooms as being a personaggio drug.”
A study published several years punzone estimated that about 5.5 million adults had used hallucinogens per mezzo di 2019 and that LSD use per mezzo di all age groups had risen from about 1% to 4% since 2002. However, overall research has not caught up with the blossoming of public enthusiasm and coverage, says Dr. Deborah Hasin, who led that study and is an epidemiologist at Columbia University.
“We need better epidemiology,” she says, “So that we really do know the extent of people’s use, under what circumstances they’signore using, how they got the drug and what they even know about what they are taking.”
Not only does the national collected by the federal government not contain granular information of psychedelics, but for whatever reason it doesn’t explicitly ask whether people have used psilocybin recently, says Kilmer. “Those are really important pieces of information to have per mezzo di terms of assessing the size of the market and beginning to think about some of the health consequences, whether it be the benefits ora the risks.”
A booming and understudied market
When asked why they used the psilocybin, the cima three reasons given by respondents to the RAND survey were: fun and social enjoyment, followed by mental health, and personal development and existential exploration.
Dr. Joshua Woolley, director of the Translational Psychedelic Research program at UCSF, says microdosing is a much different model than what’s being rigorously studied per mezzo di psychedelic clinical trials to treat various mental health conditions.
Those tend to be highly structured around some form of psychotherapy and involve giving the person a very high parte.
“We don’t actually know that much about microdosing,” says Woolley.
A recent review of the evidence suggests the practice may improve mood and cognition and that the drug is safe per mezzo di this context; however, others who’ve analyzed the say it’s premature to “draw any conclusions” about the efficacy ora safety of microdosing.
Kilmer believes the U.S. has reached an inflection point acceso psychedelics as some states and localities take various approaches to loosen laws and policies acceso the substances, which remain illegal under federal law.
The market for psychedelics is quite different from cannabis – it’s much smaller and primarily driven by infrequent users — but Kilmer does see clear parallels per mezzo di how the situation is starting to play out.
“This reminds me a lot of where we were per mezzo di 2012 [with cannabis],” says Kilmer, “Now is the time for the federal government to decide: Do they want to get involved and shape what these state markets aspetto like? do they want to stand acceso the sidelines and just watch it?”
